HRP20040439A2 - Substituted benzopyrans as selective estrogen receptor-beta agonists - Google Patents

Substituted benzopyrans as selective estrogen receptor-beta agonists Download PDF

Info

Publication number
HRP20040439A2
HRP20040439A2 HR20040439A HRP20040439A HRP20040439A2 HR P20040439 A2 HRP20040439 A2 HR P20040439A2 HR 20040439 A HR20040439 A HR 20040439A HR P20040439 A HRP20040439 A HR P20040439A HR P20040439 A2 HRP20040439 A2 HR P20040439A2
Authority
HR
Croatia
Prior art keywords
image
solution
preparation
mmol
formula
Prior art date
Application number
HR20040439A
Other languages
English (en)
Croatian (hr)
Inventor
Alan Dodge Jeffrey
Gary Krishnan Venkatesh
Willis Iii Lugar Charles
Lee Neubauer Blake
Hurst Norman Bryan
Allen Pfeifer Lance
Ivo Richadson Timothy
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20040439A2 publication Critical patent/HRP20040439A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
HR20040439A 2001-11-19 2002-11-07 Substituted benzopyrans as selective estrogen receptor-beta agonists HRP20040439A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11
PCT/US2002/033622 WO2003044006A1 (fr) 2001-11-19 2002-11-07 Benzopyrans substitues convenant comme agonistes du recepteur aux oestrogenes beta

Publications (1)

Publication Number Publication Date
HRP20040439A2 true HRP20040439A2 (en) 2005-04-30

Family

ID=26988373

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040439A HRP20040439A2 (en) 2001-11-19 2002-11-07 Substituted benzopyrans as selective estrogen receptor-beta agonists

Country Status (23)

Country Link
US (1) US7217734B2 (fr)
EP (1) EP1448544B1 (fr)
JP (1) JP4381810B2 (fr)
KR (1) KR100950616B1 (fr)
CN (1) CN1312147C (fr)
AT (1) ATE362471T1 (fr)
AU (1) AU2002359283B2 (fr)
CA (1) CA2467013C (fr)
CY (1) CY1106726T1 (fr)
DE (1) DE60220179T2 (fr)
DK (1) DK1448544T3 (fr)
EA (1) EA007382B1 (fr)
EC (1) ECSP045113A (fr)
ES (1) ES2286322T3 (fr)
HR (1) HRP20040439A2 (fr)
HU (1) HU229351B1 (fr)
IL (3) IL161325A0 (fr)
MX (1) MXPA04004703A (fr)
NO (1) NO328563B1 (fr)
NZ (1) NZ531850A (fr)
PL (1) PL205733B1 (fr)
PT (1) PT1448544E (fr)
WO (1) WO2003044006A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1626974T1 (sl) * 2003-04-21 2009-02-28 Lilly Co Eli Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
ATE457308T1 (de) 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CA2578164A1 (fr) 2004-09-07 2006-03-16 Wyeth 6h-[1]benzopyrano[4,3-b]quinolines et leur utilisation comme agents oestrogenes
US7354951B2 (en) 2004-10-18 2008-04-08 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
DK1812417T3 (da) * 2004-11-18 2009-02-16 Janssen Pharmaceutica Nv Nye 2H-chromenderivater som selektive östrogenreceptormodulatorer
EP1853578A1 (fr) 2005-02-15 2007-11-14 Eli Lilly And Company Tetralines substituees utilisees comme antagonistes selectifs du recepteur d'oestrogenes beta
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
JP2016539954A (ja) 2013-12-05 2016-12-22 カロ ファーマ エービーＫａｒｏ Ｐｈａｒｍａ Ａｂ 中皮腫の処置で使用するためのエストロゲン受容体ベータアゴニスト
JP6978420B2 (ja) 2015-09-17 2021-12-08 オハイオ・ステート・イノヴェーション・ファウンデーション カルボラン化合物及びその使用方法
WO2021183760A1 (fr) * 2020-03-11 2021-09-16 Ohio State Innovation Foundation Méthodes de modulation de l'activation des lymphocytes t à l'aide d'agonistes du récepteur bêta des œstrogènes (erβ)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
AU715528B2 (en) 1995-09-08 2000-02-03 Karo Bio Ab Orphan receptor
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
EE200100526A (et) 1999-04-16 2002-12-16 Astrazeneca Ab Östrogeeni ß-retseptori ligandid
PT1246814E (pt) 1999-12-30 2005-07-29 Signal Pharm Llc Compostos e metodos para a modulacao de receptores de estrgenio
US7214706B2 (en) 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
DE60130748T2 (de) 2000-03-27 2008-07-17 N.V. Organon Nicht-steroidale tetracyclische verbindungen für östrogen-verwandte behandlungen
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
WO2003044006A1 (fr) 2003-05-30
JP4381810B2 (ja) 2009-12-09
EP1448544B1 (fr) 2007-05-16
EA200400695A1 (ru) 2004-12-30
EA007382B1 (ru) 2006-10-27
CN1589268A (zh) 2005-03-02
JP2005513027A (ja) 2005-05-12
AU2002359283A1 (en) 2003-06-10
IL185867A (en) 2009-09-22
CN1312147C (zh) 2007-04-25
KR100950616B1 (ko) 2010-04-01
DE60220179T2 (de) 2008-02-07
ATE362471T1 (de) 2007-06-15
HK1068349A1 (en) 2005-04-29
MXPA04004703A (es) 2004-08-19
EP1448544A1 (fr) 2004-08-25
DK1448544T3 (da) 2007-10-08
PL205733B1 (pl) 2010-05-31
NZ531850A (en) 2007-01-26
KR20040063963A (ko) 2004-07-15
PL374510A1 (en) 2005-10-31
DE60220179D1 (de) 2007-06-28
IL161325A0 (en) 2004-09-27
IL161325A (en) 2008-07-08
HUP0402628A2 (hu) 2005-04-28
CY1106726T1 (el) 2012-05-23
AU2002359283B8 (en) 2003-06-10
NO328563B1 (no) 2010-03-22
AU2002359283B2 (en) 2007-06-21
PT1448544E (pt) 2007-08-10
IL185867A0 (en) 2008-01-06
ECSP045113A (es) 2004-07-23
CA2467013C (fr) 2010-08-10
HU229351B1 (en) 2013-11-28
US7217734B2 (en) 2007-05-15
CA2467013A1 (fr) 2003-05-30
NO20042583L (no) 2004-06-18
US20040249167A1 (en) 2004-12-09
ES2286322T3 (es) 2007-12-01

Similar Documents

Publication Publication Date Title
EP1618102B1 (fr) Benzopyranes substitues utiles en tant qu'agonistes selectifs du recepteur beta des oestrogenes
IL185867A (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
US7585985B2 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
KR19980702414A (ko) 벤조피란 함유 화합물 및 이들의 사용방법
EP1024802A1 (fr) ACIDES (3$i(R), 4$i(R)) - $g(D)?8 - TETRAHYDROCANNABINOL - 11 - OIQUE S'UTILISANT COMME AGENTS ANTI-INFLAMMATOIRES ET ANALGESIQUES
ES2361031T3 (es) Benzopiranos sustituidos como agonistas selectivos del receptor beta de estrógenos.
US6630508B1 (en) Substituted benzopyrans as selective estrogen receptor β agonists
EP1790644A1 (fr) Benzopyranes substitués comme agonists du receptor beta-estrogen
HK1068349B (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2003074044A1 (fr) Benzopyranes substitues utilises comme agonistes selectifs des recepteurs des oestrogenes beta

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20111027

Year of fee payment: 10

OBST Application withdrawn